No Reduction in VTE, Death With Rivaroxaban Post-Discharge No Reduction in VTE, Death With Rivaroxaban Post-Discharge

MARINER trial results showed no benefit in reducing a composite of symptomatic venous thromboembolism and death after discharge in high-risk hospitalized patients, although bleeding risk was also low.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Cardiology News Source Type: news